#Ireland #Dublin #Jazz Pharmaceuticals #Epidiolex #Xywav

Jazz Pharmaceuticals Reports First Quarter 2026 Financial Results

On May 5, 2026, Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced its financial performance for the first quarter of 2026, revealing a robust growth trajectory and positive outlook for the year ahead. The company reported total revenues of $1.1 billion, marking a 19% increase compared to the previous year. This increase highlights Jazz's effective commercial execution across its various product lines and solidifies its position within the biopharmaceutical sector.

Key Highlights of the Quarter

Jazz's CEO, Renee Gala, reflected on the results, emphasizing the company's disciplined execution strategy and the successful advancement of key pipeline products. Among the notable achievements this quarter:

• - Xywav® continued to perform well, with revenues growing by 18% year-over-year, attributed to the strong adoption of its low-sodium formulation. With an addition of 425 net new patients, total active patients reached approximately 16,600, comprising both narcolepsy and idiopathic hypersomnia patients.
• - Epidiolex® revenues rose 15% year-over-year, driven by consistent demand and a newly formed agreement with Nippon Zoki for the commercialization of Epidyolex in Japan, pending regulatory approvals.
• - Zanidatamab, an innovative treatment for HER2 positive gastroesophageal adenocarcinoma, has progressed towards its potential launch with a priority review granted by the FDA, set for August 25, 2026.

These advancements in the product pipeline are expected to significantly contribute to Jazz’s efforts to deliver life-changing therapies for patients with rare diseases and fuel long-term sustainable growth.

Detailed Financial Performance Overview

The financials reflect substantial revenue increases in various segments:

• - Total revenues reached $1,068.9 million, up from $897.8 million in Q1 2025.
• - GAAP net income saw notable improvement, amounting to $293.1 million compared to a loss of $92.5 million a year prior. Moreover, adjusted earnings per share were reported at $6.34.
• - Operating cash flow totaled $408 million, showcasing strong business operations and financial discipline.

Cost and Expense Management

Operating expenses have been strategically managed, with selling, general and administrative costs decreasing from $514 million in the previous year to $352.7 million this quarter. Research and development expenses slightly rose to $196 million, reflecting Jazz's ongoing commitment to innovation and product development. The company's effective management strategies have enhanced gross margins, which remained high at approximately 87.5% for the quarter.

Future Outlook

Looking forward, Jazz Pharmaceuticals has reaffirmed its guidance for 2026, expecting total revenues to be in the range of $4,250 million to $4,500 million. With several new product launches anticipated along with pipeline advancements, Jazz is poised for robust growth in the remainder of the year.

A conference call was held on the same day to discuss these results in further detail, allowing analysts and investors an opportunity to gain insights into the strategies driving the company’s success. Jazz is committed to expediting the rollout of emerging therapies that can dramatically improve patients’ quality of life, reaffirming its dedication to its mission of transforming patient care.

About Jazz Pharmaceuticals

Headquartered in Dublin, Ireland, Jazz Pharmaceuticals is a global biopharmaceutical company devoted to innovating treatments that address the needs of patients suffering from rare diseases. It focuses on developing and commercializing a diverse range of leading therapies for conditions such as sleep disorders, epilepsy, and cancers. For more information about Jazz Pharmaceuticals and its offerings, visit Jazz Pharmaceuticals Official Website.